Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial
Table 7
Adverse events observed in CRC patients in adjuvant/palliative chemotherapy with FOLFOX4 ().
After 1 chemotherapy cycle (FOLFOX4)
After 6 chemotherapy cycles (FOLFOX4)
Grade refers to the severity of the AE*
Grade refers to the severity of the AE
0
1
2
3
4
0
1
2
3
4
Hemoglobin
82.9
12.2
4.9
0
0
76.9
17.9
2.6
0
0
Leukocytes (total WBC)
97.6
2.4
0
0
0
74.4
5.1
15.4
5.1
0
Neutrophils/granulocytes
85.4
7.3
0
4.9
2.4
48.7
12.8
10.3
17.9
7.7
Lymphocytes
95.1
0
4.9
0
0
92.3
0
7.7
0
0
Platelets
97.6
0
2.4
0
0
84.6
10.3
5.1
0
0
Weight loss
82.9
9.8
2.4
4.9
0
92.3
0
2.6
5.1
0
Hyperglycemia
97.6
0
0
2.4
0
87.2
0
7.7
5.1
0
γ-glutamyl transpeptidase
100
0
0
0
0
89.8
10.2
0
0
0
Alkaline phosphatase
100
0
0
0
0
84.6
15.4
0
0
0
Neuropathy: sensory
100
0
0
0
0
94,9
0
5.1
0
0
Infection with Grade 3 or 4 neutrophils
100
0
0
0
0
97.4
0
2.6
0
0
Diarrhea
100
x
0
0
0
92.3
x
7.7
0
0
Values expressed as % of the patients who had AE. *Grade refers to the severity of the AE: grade 1 = mild AE; grade 2 = moderate AE; grade 3 = severe AE; grade 4 = life-threatening or disabling AE; grade 5 = death related to an AE [22].